Skip to main content

Advertisement

SpringerLink
Log in

Anemia in heart failure: To treat or not to treat?

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Anemia is a prevalent comorbidity in chronic heart failure (CHF). As studies have demonstrated close links between anemia and a poorer prognosis, there has been an interest in developing treatment strategies for this condition. Anemia is closely associated with disease severity and may be secondary to multiple modifiable causes; therefore, the initial strategies should always include a thorough search for etiology and should focus on optimizing heart failure treatment. Recently, more specific therapies have been assessed, namely erythropoiesis-stimulating agents and iron supplementation therapy. Studies evaluating erythropoietin in heart failure have demonstrated conflicting results to date, with smaller, singlecenter studies seeming to show a clinical benefit and larger, multicenter trials demonstrating no significant effect on clinical outcome aside from improvement in selected quality-of-life indices. Similarly, studies evaluating iron therapy alone in anemic patients with heart failure have so far shown promising results with regard to clinical and quality-of-life outcomes, but these studies are limited in that they involved small patient numbers. Ongoing studies such as the Reduction of Events With Darbepoetin Alfa in Heart Failure (RED-HF), Iron Supplementation in Heart Failure Patients With Anemia (IRON-HF), and Ferinject Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) trials will determine the value of darbepoetin alfa and intravenous iron replacement therapy in anemic CHF patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. World Health Organization: Nutritional Anaemias: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 1968.

    Google Scholar 

  2. Felker GM, Adams KF Jr, Gattis WA, O’Connor CM: Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 2004, 44:959–966.

    Article  PubMed  Google Scholar 

  3. Anand IS: Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev 2008, 13:379–386.

    Article  PubMed  Google Scholar 

  4. Androne AS, Katz SD, Lund L, et al.: Hemodilution is common in patients with advanced heart failure. Circulation 2003, 107:226–229.

    Article  PubMed  Google Scholar 

  5. Murphy NF, McDonald K: Treatment of anaemia in chronic heart failure—optimal approach still unclear. Eur Heart J 2007, 28:2185–2187.

    Article  PubMed  CAS  Google Scholar 

  6. Silverberg DS, Wexler D, Blum M, et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737–1744.

    Article  PubMed  CAS  Google Scholar 

  7. Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46:e1–e82.

    Article  PubMed  Google Scholar 

  8. Mancini DM, Katz SD, Lang CC, et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294–299.

    Article  PubMed  CAS  Google Scholar 

  9. Palazzuoli A, Silverberg D, Iovine F, et al.: Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006, 152:1096.e9–1096.e15.

    Article  Google Scholar 

  10. Palazzuoli A, Silverberg DS, Iovine F, et al.: Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007, 154:645.e9–645.e15.

    Article  Google Scholar 

  11. Silverberg DS, Wexler D, Sheps D, et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775–1780.

    Article  PubMed  CAS  Google Scholar 

  12. Bolger AP, Bartlett FR, Penston HS, et al.: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006, 48:1225–1227.

    Article  PubMed  CAS  Google Scholar 

  13. Okonko DO, Grzeslo A, Witkowski T, et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008, 51:103–112.

    Article  PubMed  CAS  Google Scholar 

  14. Toblli JE, Lombraña A, Duarte P, Di Gennaro F: Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007, 50:1657–1665.

    Article  PubMed  CAS  Google Scholar 

  15. Ghali JK, Anand IS, Abraham WT, et al.: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008, 117:526–535.

    Article  PubMed  CAS  Google Scholar 

  16. Ponikowski P, Anker SD, Szachniewicz J, et al.: Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007, 49:753–762.

    Article  PubMed  CAS  Google Scholar 

  17. van Veldhuisen DJ, Dickstein K, Cohen-Solal A, et al.: Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007, 28:2208–2216.

    Article  PubMed  Google Scholar 

  18. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381–388.

    Article  PubMed  CAS  Google Scholar 

  19. Singh AK, Szczech L, Tang KL, et al.: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085–2098.

    Article  PubMed  CAS  Google Scholar 

  20. Drueke TB, Locatelli F, Clyne N, et al.: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071–2084.

    Article  PubMed  CAS  Google Scholar 

  21. Henke M, Laszig R, Rube C, et al.: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003, 362:1255–1260.

    Article  PubMed  CAS  Google Scholar 

  22. Leyland-Jones B, Semiglazov V, Pawlicki M, et al.: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005, 23:5960–5972.

    Article  PubMed  CAS  Google Scholar 

  23. RED-HF Trial—Reduction of Events With Darbepoetin Alfa in Heart Failure Trial (ClinicalTrials.gov identifier: NCT00358215). Available at http://clinicaltrials.gov/ct2/show/NCT00358215. Accessed May 22, 2008.

  24. Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, et al.: Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail 2007, 13:14–17.

    Article  PubMed  CAS  Google Scholar 

  25. Ferinject Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) (ClinicalTrials.gov identifier: NCT00520780). Available at http://clinicaltrials.gov/ct2/show/NCT00520780. Accessed May 22, 2008.

  26. Cavill I, Auerbach M, Bailie GR, et al.: Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006, 22:731–737.

    Article  PubMed  CAS  Google Scholar 

  27. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005, 352:1011–1023.

    Article  PubMed  CAS  Google Scholar 

  28. Wu WC, Rathore SS, Wang Y, et al.: Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001, 345:1230–1236.

    Article  PubMed  CAS  Google Scholar 

  29. Rao SV, Jollis JG, Harrington RA, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004, 292:1555–1562.

    Article  PubMed  CAS  Google Scholar 

  30. Hebert PC, Wells G, Blajchman MA, et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999, 340:409–417.

    Article  PubMed  CAS  Google Scholar 

  31. Hebert PC, Tinmouth A, Corwin HL: Controversies in RBC transfusion in the critically ill. Chest 2007, 131:1583–1590.

    Article  PubMed  Google Scholar 

  32. Krantz SB: Erythropoietin. Blood 1991, 77:419–434.

    PubMed  CAS  Google Scholar 

  33. Jelkmann W: Molecular biology of erythropoietin. Intern Med 2004, 43:649–659.

    Article  PubMed  CAS  Google Scholar 

  34. Wright GL, Hanlon P, Amin K, et al.: Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004, 18:1031–1033.

    PubMed  CAS  Google Scholar 

  35. Statement of John K. Jenkins, MD, Director, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, before Committee on Ways and Means, Subcommittee on Health, United States House of Representatives. Available at http://www.fda.gov/ola/2007/esa062607.html. Accessed May 22, 2008.

  36. Macdougall IC, Cooper AC: Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002, 17(Suppl 11):39–43.

    PubMed  CAS  Google Scholar 

  37. Winearls CG: Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998, 13(Suppl 2):3–8.

    Article  PubMed  CAS  Google Scholar 

  38. Fisher JW: Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003, 228:1–14.

    CAS  Google Scholar 

  39. Egrie JC, Dwyer E, Browne JK, et al.: Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003, 31:290–299.

    Article  PubMed  CAS  Google Scholar 

  40. van Veldhuisen DJ, McMurray JJ: Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007, 9:110–112.

    Article  PubMed  Google Scholar 

  41. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12,065 patients with new-onset heart failure. Circulation 2003, 107:223–225.

    Article  PubMed  Google Scholar 

  42. Nanas JN, Matsouka C, Karageorgopoulos D, et al.: Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006, 48:2485–2489.

    Article  PubMed  Google Scholar 

  43. Cavill I: Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 2003, 18(Suppl 8):viii24–viii28.

    PubMed  CAS  Google Scholar 

  44. Deicher R, Horl WH: New insights into the regulation of iron homeostasis. Eur J Clin Invest 2006, 36:301–309.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Heart Failure Unit, St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland

    Kenneth McDonald

Authors
  1. George Mak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niamh F. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth McDonald
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth McDonald.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mak, G., Murphy, N.F. & McDonald, K. Anemia in heart failure: To treat or not to treat?. Curr Treat Options Cardio Med 10, 455–464 (2008). https://doi.org/10.1007/s11936-008-0038-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-008-0038-5

Keywords

Search

Navigation